IMMUNEERING CORP - CLASS A (IMRX) Stock Price, Quote, News and Overview
NASDAQ:IMRX - Nasdaq - US45254E1073 - Common Stock
IMRX Quote and Key Statistics
IMMUNEERING CORP - CLASS A
NASDAQ:IMRX (1/22/2025, 8:00:02 PM)
Premarket: 2.025 -0.08 (-4.03%)2.11
-0.01 (-0.47%)
IMRX Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -72.74% | ||
| ROE | -84.56% | ||
| Debt/Equity | 0 |
IMRX Performance and Technical Analysis
IMRX Ownership and Analysts
IMRX Latest News and Analysis
Curious about the stocks that are showing activity before the opening bell on Tuesday?
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
Why Is Immuneering Stock Trading Higher On Tuesday?
On Tuesday, Immuneering Corporation (NASDAQ:IMRX) revealed data updates from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104 and plans to expand the Phase 2a trial to include three additional combination arms. Updated data from the Phase 2a arm of IMM-1-104 with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer shows: As of December 5, 2024, three patients achieved complete or partial responses for an overall response rate of 43% (3/7) and a
Why Is Immuneering Stock Trading Higher On Tuesday?
Immuneering reveals promising Phase 2a pancreatic cancer trial updates for IMM-1-104, showcasing efficacy, safety, and future expansion plans.
About IMRX
Company Profile
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2021-07-30. The firm is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the MAPK pathway. The Company’s second product candidate, IMM-6-415, aims to achieve universal-MAPK activity with an accelerated twice-daily oral dosing cadence, also through deep cyclic inhibition of the MAPK pathway. IMM-6-415 is in Investigational New Drug application (IND), enabling studies. Its pipeline also includes Trifecta MEK, RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
Company Info
IMMUNEERING CORP - CLASS A
245 Main Street, Second Floor
Cambridge MASSACHUSETTS US
CEO: Benjamin J. Zeskind
Employees: 66
Company Website: https://immuneering.com/
Investor Relations: https://ir.immuneering.com/
Phone: 16175008080
IMRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.74 | 299.00B | ||
| AMGN | AMGEN INC | 14.23 | 146.98B | ||
| GILD | GILEAD SCIENCES INC | 21 | 115.95B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839.22 | 110.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.97 | 74.73B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.38B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.75B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.66B | ||
| NTRA | NATERA INC | N/A | 22.70B | ||
| BIIB | BIOGEN INC | 8.74 | 20.80B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.34B |